PD-1/VEGF Bispecific

PD-1/VEGF bispecific is the 康方生物-anchored mechanism in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位. The episode describes a Chinese phase-3 readout where a PD-1/VEGF bispecific showed strong progression-free-survival data against K药 in the source’s account, making the asset difficult for global pharma to ignore.

The source is careful about uncertainty. 小P老师 says the mechanism is not fully explained, with possible explanations including same-molecule synergy or tumor-local concentration. 默沙东 is described as publicly asking for overall-survival evidence while still acting defensively through later Chinese asset buying.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 adds a sharper endpoint caveat through Progression-Free vs Overall Survival. The episode says VEGF-related effects may help shrink tumors and improve PFS, while OS is harder to improve and interpret because resistance, subsequent therapy, and patient condition complicate the final survival signal.

Key Claims

• PD-1/VEGF bispecifics try to combine immune-checkpoint and angiogenesis-related intervention in one molecule.
• The episode treats Akeso’s data as a major China-biotech signal, not as settled proof that the mechanism will always beat PD-1 monotherapy.
• Mechanistic uncertainty and final survival data remain important.
• The asset category is commercially strategic because it sits near PD-1 Market Saturation and Multinational Pharma Patent-Cliff Anxiety.
• Episode 156 adds that PFS strength should be distinguished from still-contested OS evidence.

Connections

• Akeso / 康方生物, Merck / 默沙东, and Keytruda / K药 - source company and comparator context.
• Cancer Immune Recognition Problem - immune-treatment background.
• China Biotech Asset Repricing and Biotech License-Out Arbitrage - transaction context.
• Finite-Game Biotech Competition - mature-market differentiation frame.
• Summit Therapeutics, Progression-Free vs Overall Survival, and Biotech BD Data Validation Phase - 2026 evidence-readout context.